Metabolus was formed with a team of scientists, clinicians, and development experts to translate research into diagnostic Autism Spectrum Disorder products and services.
William A. Alaynick, Ph.D., President and CEO. Dr. Alaynick is leading the commercial development of Metabolus’ proprietary and patent-pending methods and products. As a founder of ScholarNexus, he has worked to translate academic discoveries to commercial utility. He has expertise in federal funding, most recently at NanoCellect where he helped raise $6M+ in non-dilutive funding. He received his PhD from UCSD and completed postdoctoral training at The Salk Institute for Biological Studies.
Robert K. Naviaux, M.D., Ph.D., Chair, Scientific Advisory Board. Dr. Naviaux has 20+ years of clinical practice in treating children with metabolic disease via a wide rage of diagnostic modalities. He founded the Mitochondrial and Metabolic Disease Center and discovered the molecular/genetic basis of Alper’s Syndrome, a defect in mitochondrial DNA polymerase. Dr. Naviaux received his MD and PhD from the Indiana School of Medicine and completed a postdoctoral fellowship at The Salk Institute for Biological Studies.
Metabolus is supported within the ScholarNexus Accelerator that provides access to the ScholarNexus team, wet and dry laboratory space, administrative infrastructure, and seed funding.